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Many microRNAs (miRNAs) are evolutionarily
conserved and have intriguing expression pat-
terns. Tissue and/or time-specific expressions
of some miRNAs are presumably controlled by
unique cis-acting regulatory elements that co-
evolved with the miRNA sequences. Exploiting
bioinformatics, we identified several miRNAs
whose primary transcripts could be regulated
by conserved genomic elements proximal to
their transcription start sites. Such miRNAs in-
cludemicroRNA-223 (miR-223), which is report-
edly controlled by a unique regulatory mecha-
nism during granulopoiesis. Here, we define a
mechanism distinct from that previously pro-
posed to regulate miR-223 expression. We find
that the mir-223 gene resembles a ‘‘myeloid
gene’’ and might be driven by the myeloid tran-
scription factors, PU.1 and C/EBPs. This mech-
anism is specified by the conserved proximal
cis-regulatory element and might be common
among different species. Hence, it needs to be
considered that two distinct mechanisms that
would play critical roles in myeloid functions
and differentiation are actually concerned with
the regulation of miR-223.
INTRODUCTION
The miRNAs are a growing class of tiny noncoding RNAs
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and
Ambros, 2001) that regulate the expression of genes
by hybridizing the target sites with complementary se-
quences that are followed by translational repression,
mRNA cleavage, or destabilization (Bartel, 2004; Yektaet al., 2004). Hundreds of miRNAs have been found in
various organisms, and many miRNAs are evolutionarily
conserved, suggesting their potential roles in essential
physiological events (Bartel, 2004). Some miRNAs have
limited expression patterns with strict tissue, cell, and
temporal specificities, while others demonstrate ubiqui-
tous or constitutive expression (Pasquinelli et al., 2005).
Therefore, studies of regulatory mechanisms governing
expression of specific miRNAs would contribute to better
understanding of their physiological roles.
Despite growing knowledge on miRNA biology, little is
known about the transcriptional regulation of miRNAs.
However, cumulative evidence suggests that many
miRNAs are transcribed by RNA polymerase II (Lee et al.,
2004). This is consistent with spatiotemporally limited
expression of miRNAs and indicates that numerous
lineage-specific transcription factors would take part in
transcriptional regulation of miRNAs. It is now widely ac-
cepted that most miRNAs are transcribed from their own
promoters, even though a few primary transcripts have
been fully defined to date. These primary miRNA tran-
scripts, called pri-miRNAs, are generally thought to be
much longer than the conserved stem loops currently
used to define miRNA genes, as suggested by several ob-
servations. For example, clustered miRNAs are generated
from a single primary transcript (Lagos-Quintana et al.
2001; Lau et al. 2001). Furthermore, some RT-PCR exper-
iments amplified large fragments of the pri-miRNAs (Lee
et al. 2002). Identification of full-length primary transcripts
with regulatory genomic elements would therefore be
a critical step for studying the transcriptional mechanisms
for every single miRNA.
The hematopoietic system is a paradigm for the differ-
entiation of distinct cell lineages from multipotent progen-
itors (Orkin and Zon, 2002). Although lineage commitment
decisions in hematopoiesis involve a variety of modulators
that are influenced by each other in an unusually complex
manner, the central role of transcription factors in this bio-
process has been highlighted to date (Sieweke and Graf,Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 617
1998; Zhu and Emerson, 2002). The current concept fa-
vors the emerging hematopoietic lineages being con-
trolled by a unique combination of transcription factors,
each of which may appear singly in different lineages (Sie-
weke and Graf, 1998), rather than the lineages being
regulated by single master transcription factors. Thus,
diverse combinations of transcription factors specify the
fate of distinct cell types by selection and maintenance
of a lineage-specific gene-expression program.
Previous studies demonstrated that some miRNAs,
such asmiR-142,miR-181, andmiR-223, are preferentially
expressed in the hematopoietic system (Chen et al., 2004;
Chen and Lodish, 2005). For example, miR-181 is highly
expressed in lymphoid tissues and cells (Chen et al.,
2004). Ectopic expression of miR-181 in murine hemato-
poietic progenitors resulted in significant increase of B
lineage fraction, underscoring possible miRNA involve-
ment in lymphopoiesis (Chen et al., 2004). Furthermore,
a very recent study demonstrated the mechanism that
specifies myeloid expression of miR-223 and proposed
a unique ‘‘minicircuitry’’ comprised of miR-223 and tran-
scription factors, NFI-A and CAAT enhancer-binding pro-
tein a (C/EBPa; Fazi et al., 2005). As shown previously,
miR-223 is highly conserved, and its myeloid-specific
expression is also well characterized in both human and
mouse (Chen et al., 2004; Fazi et al., 2005), suggesting
that the regulatory system is expected to be phylogeneti-
cally conserved.
Here, we demonstrate a comprehensive strategy for un-
derstanding miRNA gene expression and make use of
transcriptome data, an integrated database of genome
sequences or transcription factors, and bioinformatics;
in addition, we follow experimental validation. With this
approach, we identified dozens of cDNAs encoding
miRNA precursor sequences. These cDNAs are actually
considered as pri-miRNAs, and some of them are charac-
terized with genomic information that implicates for their
regulatory mechanisms.
As a result of this screening, we defined a regulatory
mechanism for myeloid expression of miR-223, which is
distinct from the previously proposed machinery but
would be common among different species. We thus
found that miR-223 originates in a relatively long noncod-
ing RNA (pri-miR-223) driven by the conserved proximal
genomic element in which possible binding sites for mye-
loid transcription factors, PU.1 and C/EBP, are present.
Our analyses revealed an essential role of PU.1 in tran-
scription of pri-miR-223. Moreover, C/EBP was shown
to strongly enhance the promoter activity, especially in
combination with PU.1. Therefore, the conserved proxi-
mal cis-acting regulatory element of pri-miR-223 shows
general myeloid promoter characteristics, consistent
with preferential expression of miR-223 in the myeloid lin-
eage. This evolutionarily conserved promoter is distinct
from the previously characterized promoter (Fazi et al.,
2005). Importantly, our reassessment revealed that this
conserved promoter is probably active in the induction
of miR-223 during All-trans retinoic acid (ATRA)-induced618 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.differentiation of the APL cell line, NB4 cells, which is the
main experimental system adopted in the previous study
(Fazi et al., 2005). As a result of our study on miR-223 reg-
ulation and our reassessment of some parts in the previ-
ous report, it needs to be considered how two distinct
mechanisms regulate the expression of miR-223.
RESULTS
Genome-Wide Screening and Characterization
of Primary miRNA Transcripts
It is now widely accepted that many miRNAs are tran-
scribed by RNA polymerase II (Lee et al., 2004; Kim,
2005). Therefore,we hypothesized that primary transcripts
of some miRNAs could appear as mRNA-like RNAs.
Recent fruits of FANTOM3, the project of mouse transcrip-
tome analyses, published approximately 103,000 non-
redundant cDNA sequences fromvarious tissues (Carninci
et al., 2005). Based upon the above hypothesis, we made
useof this library for genome-wide screening ofmRNA-like
primary miRNAs. As an initial approach, we searched for
cDNAs encoding full-length miRNA precursor sequences
and reasoned that such cDNAs represent primary tran-
scripts of ‘‘exonic’’ miRNAs (Kim and Nam, 2006).
Based on the homology, 102,802 cDNAs of the
FANTOM3 database were exhaustively aligned with the
337 registered murine miRNA precursor sequences by
BLASTN program (Figure 1A). We identified 42 pairings
of cDNA-pre-miRNAs with a perfect match (Table 1). The
majority of these miRNA precursors is present on paired
cDNAs with +/+ direction, while a few miRNA precursors
are on paired cDNAs with opposite direction (+/; Table
1). Although these antisense transcripts could be involved
in important gene-regulatory events as reported recently
(Katayama et al., 2005), we excluded them from the candi-
dates for this round of screening.
As is well known, 50 genomic regions proximal to tran-
scription start sites often act as critical cis-regulatory
elements for gene transcription (Lipman, 1997; Venkatesh
and Yap, 2004). Moreover, such proximal cis-acting regu-
latory elements are often highly conserved among differ-
ent species. To identify 50 proximal cis-regulatory ele-
ments for each pri-miRNA candidate, we then extracted
upstream genomic regions of 38 cDNAs paired with pre-
miRNAs with a +/+ direction (Figure 1A). A BLAT search
of a 250 bp upstream sequence of each cDNA screened
out 12 pri-miRNA candidates whose 50 proximal genomic
regions are highly conserved among mouse, rat, dog, and
human (Table 2). Putative binding motifs for transcription
factors of these 12 regions were then explored by con-
ducting the TESS program (Table 2).
Our screening strategy heredemonstrated that available
cDNA libraries might be sources of information on mRNA-
like primary transcripts of miRNAs. Furthermore, subse-
quent genome-based profiling of pri-miRNA indicated
that some miRNA sequences might have coevolved with
genomic elements residing close to their transcription start
sites. Such genomic elements contain several consensus
Figure 1. Mouse Pri-miR-223 Identified by Genome-Wide Screening of Pri-miRNAs
(A) Schematic for identification of cDNAs encoding known pre-miRNA sequences with conserved upstream genomic regions in FANTOM3.
(B) Two cDNAs, AK036748 and AK170206, encoding murine miR-223 precursor sequences (upper panel) and their gene structures (lower). The num-
bers denote the corresponding position at the Mus musculus genomic clone, RP23-23B17.
(C) Conservation of pri-miR-223 50 proximal genomic region (upper). A luciferase reporter assay was performed in RAW264.7 cells with indicated
reporters (lower). 1 indicates ppri-mmiR-223758-Luc, 2 indicates ppri-mmiR-223476-Luc, 3 indicates ppri-mmiR-223233-Luc, 4 indicates
ppri-mmiR-223146-Luc, 5 indicates ppri-mmiR-22377-Luc, and 6 indicates pGL3 basic.
(D) Upper panel: The 50 proximal promoter region of mouse pri-miR-223 with putative bindingmotifs for several transcription factors. The transcription
start site of AK036748 is fixed as +1. Lower panel: Highly conserved genomic site that contains PU.1- and C/EBP-binding motifs.motifs for intriguing transcription factors (Table 2), sug-
gesting that these conserved genomic regions would act
as cis-acting regulatory elements for pri-miRNAs and
that miRNA expression might be regulated by such tran-
scription factors.
Identification of Pri-miR-223 Candidates
in FANTOM3
Of particular interest, AK170206 screened out as pri-miR-
223 is derived from the cDNA library of CD11c+ dendritic
cells (Table 1), consistent with previous studies reporting
myeloid-specific expression of miR-223 (Chen et al.,
2004). Furthermore, AK170206 could be regulated by
myeloid transcription factors, PU.1 and C/EBP, as the
conserved upstream genomic region contains binding
motifs for these transcription factors (Table 2). Thus, this
casemay represent consistency between the tissue spec-
ificity and potential regulatory transcription factors.Although another cDNA clone, AK036748, is also a can-
didate of pri-miR-223 (Table 1), we found that this clone is
practically transcribed from the same gene locus for
AK170206 (Figure 1B). Of note, the AK036748 clone is
actually expressed in vivo with strict myeloid specificity,
and ectopic expression of its splicing variant resulted in
the generation of functional mature miR-223, indicating
that AK036748 and AK170206 are probably mouse pri-
miR-223 in vivo (Figures S1 and S2).
Since the conserved genomic region found by our ge-
nome profiling was supposed to be included in the proxi-
mal promoter of pri-miR-223, the 50 flanking genomic
region was amplified from mouse genome, which was
followed by progressive deletions, and a set of reporter
vectors was generated as shown in Figure 1C. Relative re-
porter activity in miR-223-expressing monocytic cell line,
RAW264.7, was examined for each reporter vector using
a luciferase reporter assay (Figure 1C). TranscriptionalCell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 619
Table 1. Murine cDNA Clones Encoding Known miRNA Precursors
miRNAs Lengtha Strandb Clone Locationc Tissue Origin
mmu-let-7d 103 +/+ AK160312 1006–1108 Wolffian duct includes surrounding
region
mmu-let-7i 85 +/+ AK052706 109–193 kidney
mmu-mir-100 80 +/+ AK045205 1522–1601 parthenogenote
mmu-mir-101a 83 +/+ AK021368 207–289 eyeball
mmu-mir-124a-1 85 +/+ AK044422 736–820 retina
mmu-mir-130a 64 +/+ AK033350 467–530 testis
mmu-mir-133b 119 +/+ AK132542 3750–3868 head (brain, eyeball, and pituitary gland)
mmu-mir-144 66 +/+ AK158085 357–422 inner ear
mmu-mir-191 74 +/+ AK076537 788–861 head (brain, eyeball, and pituitary
gland)
mmu-mir-196b 85 +/+ AK054058 368–452 oviduct
mmu-mir-202 72 +/+ AK144366 157–228 testis
mmu-mir-205 68 +/+ AK014513 1438–1505 skin
mmu-mir-21 92 +/+ AK043091 2481–2572 cerebellum
mmu-mir-214 110 +/+ AK051872 1754–1863 eyeball
mmu-mir-22 95 +/+ AK008813 133–227 stomach
mmu-mir-22 95 +/+ AK018628 242–336 cecum
mmu-mir-22 95 +/+ AK021103 151–245 corpus striatum
mmu-mir-223 110 +/+ AK036748 2437–2546 bone (os femoris)
mmu-mir-223 110 +/+ AK170206 1937–2046 NOD-derived CD11c +ve dendritic cells
mmu-mir-331 96 +/+ AK031192 1073–1168 forelimb
mmu-mir-339 96 +/+ AK019591 2509–2604 testis
mmu-mir-377 68 +/+ AK077315 913–980 pituitary gland
mmu-mir-423 109 +/+ AK038056 266–374 thymus
mmu-mir-425 85 +/+ AK076537 1246–1330 head (brain, eyeball, and pituitary
gland)
mmu-mir-433 124 +/+ AK018276 194–317 olfactory brain
mmu-mir-451 72 +/+ AK158085 522–593 inner ear
mmu-mir-546 121 +/+ AK049271 3088–3208 ES cells
mmu-mir-678 84 +/+ AK077456 1829–1912 whole body
mmu-mir-678 84 +/+ AK144412 1827–1910 spinal cord
mmu-mir-678 84 +/+ AK145829 1829–1912 liver
mmu-mir-678 84 +/+ AK146754 1890–1973 kidney
mmu-mir-678 84 +/+ AK146966 1926–2009 heart
mmu-mir-678 84 +/+ AK159186 1835–1918 osteoclast-like cell
mmu-mir-686 109 +/+ AK133839 260–368 whole body
mmu-mir-698 109 +/+ AK163187 431–539 cerebellum
mmu-mir-705 82 +/+ AK078938 53–82 cecum
mmu-mir-705 82 +/+ AK154922 4698–4779 NOD-derived CD11c +ve dendritic cells
mmu-mir-707 73 +/+ AK030571 360–432 pituitary gland
mmu-mir-29c 88 +/ AK081202 1364–1277 corpus striatum620 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.
Table 1. Continued
miRNAs Lengtha Strandb Clone Locationc Tissue Origin
mmu-mir-29b-2 81 +/ AK081202 1871–1791 corpus striatum
mmu-mir-135a-1 90 +/ AK052709 2901–2812 kidney
mmu-mir-181b-2 89 +/ AK082091 1112–1024 cerebellum
The method used for extraction of these pre-miRNA/cDNA pairings is described in Experimental Procedures.
a Length of each predicted miRNA precursor in miRBase is shown.
bCoding direction of miRNA: cDNA pairing is shown as miRNA strand/cDNA strand.
c Position of each pre-miRNA sequence is shown as corresponding nucleotide numbers of pairing cDNA sequence.activity was readily detected in the presence of regions
that had been deleted for up to 146 bp of mouse pri-
miR-223, although significant reduction was observed
when the region from 233 bp to 146 bp was removed
(Figure 1C). Strikingly, the promoter activity was com-
pletely abolished to the basal level when the region from
146 bp to 77 bp was deleted (Figure 1C), indicating
that this region contains the essential promoter domain
for mouse pri-miR-223 transcription. Notably, this region
is actually the highly conserved region identified in the ini-
tial genome profiling and contains two binding motifs for
PU.1: one nonconventional binding site for C/EBP (Grove
and Plumb, 1993) and one site for GATA-1 (Figure 1D).
Together, our data suggest that the highly conserved
genomic region that contains consensus motifs for hema-
topoietic transcription factors is probably the core pro-
moter of mouse pri-miR-223.
Myeloid Transcription Factors Act on the Conserved
Promoter of Pri-miR-223
To examine whether the myeloid transcription factors
physically interact with the conserved promoter region
in vivo, we performed chromatin immunoprecipitation
(ChIP). DNA fragments containingmousepri-miR-223pro-
moter aswell asmouseCathepsinCpromoter were immu-
noprecipitated from genomic DNA of WEHI-3 by a-PU.1
and a-C/EBPb antibodies, suggesting that these myeloid
transcription factors are actually interactingwith the corre-
sponding promoter sites (Figure 2A).
The action of those transcription factors on the promoter
was then examined. Single expression of PU.1 weakly
activated mouse pri-miR-223 promoter in miR-223-nega-
tive NIH3T3 (Figure 2B). C/EBPb alone stimulated mouse
pri-miR-223 promoter activity, but such activation was
weakened in a dose-dependent manner (Figure 2B). How-
ever, coexpression of PU.1 and C/EBPb induced potent
promoter activity, and C/EBPb enhanced it in a dose-
dependent manner (Figure 2C), indicating that the combi-
natorial action of PU.1 and C/EBP confers stable and
high-level activity of mouse pri-miR-223 promoter.
We also examined action of GATA-1 on mouse pri-
miR-223 promoter and observed a repression of the
endogenous activity of pri-miR-223 promoter by this
transcription factor (Figure 2D). Notably, however, such
repression was observed even in the absence of theconsensus-binding motif (data not shown), implying that
GATA-1-mediated suppression of mouse pri-miR-223
promoter activity would be due to mechanisms without
its DNA binding, as previously reported elsewhere (Nerlov
et al., 2000).
Together these data suggest that the activity of mouse
pri-miR-223 promoter is highly induced in the presence
ofmyeloid transcription factors, PU.1 andC/EBP,whereas
the erythroid transcription factor GATA-1 represses it,
which is consistent with myeloid-specific expression of
miR-223.
Critical Roles of Myeloid Transcription Factors
in Mouse Pri-miR-223 Transcription
To test whether the putative binding sites for myeloid tran-
scription factors in pri-miR-223 promoter are essential for
its transcriptional activity, we introduced various muta-
tions into those binding motifs (Figure 3A) and examined
effects of those mutations on the transcriptional activity
using a luciferase reporter assay in the RAW264.7 cell
line. Although the promoter activity declined significantly
with every single mutation (mutations 1, 2, and 3; Fig-
ure 3A), the mutation in the downstream PU.1-binding
motif (mutation 2) resulted in a drastic decrease of tran-
scriptional activity (Figure 3A), suggesting a dominant
role of the corresponding site in transcriptional control of
mouse pri-miR-223. Nonetheless, the most striking effect
was observed when mutations were introduced in both of
the two binding sites for PU.1 (mutation 4) and the tran-
scriptional activity was completely abolished by this com-
bination of mutations (Figure 3A), indicating that these two
PU.1-binding sites are essential for induction of mouse
pri-miR-223 promoter activity. Mutations in all three sites
(mutation 7) logically resulted in the complete extinction
of promoter activity, too (Figure 3A). Of note, physical
binding of PU.1 to those putative binding sites was also
confirmed (Figures S3A and S3B).
These results demonstrate that transcription of mouse
pri-miR-223 is optimally induced in the presence of both
of two PU.1-binding sites in the conserved promoter,
therefore implying a critical role of PU.1 in pri-miR-223
transcription.
To further confirm the role of PU.1 in pri-miR-223 tran-
scription, we investigated the effect of dominant-negative
PU.1 (DN-PU.1) expression on pri-miR-223 promoterCell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 621
Table 2. miRNA-Containing cDNAs with Conserved Upstream Genomic Elements
cDNAs (miRNAs)
Chromosome, Strand,
Positiona Transcription Factors and Consensus Sequences
AK021368
(mmu-mir-101A)
4() ZF5 (1b) [GGCGCG] IL-6 RE-BP (1) [CTGGAA]
100854121–100854208 C/EBPb (1) [CTGGRAA] Sp1 (1) [GGCGGG]
AK144366
(mmu-mir-202)
7() GR (1) [TGTGCC] RAP1 (1) [CANCCNNNCA]
139809438–139809493 TDEF (1) [CACGTG] CAC-binding protein (1) [GGGGTG]
C-Myb (1) [GGTGAG]
NF-1/L (1) [TTGGCA] NF-1 (-like proteins) (1) [CTTGGC]
AK018628
AK008813
(mmu-mir-22)
11(+) Sp1 (1) [GTGGGTGTGGc (GTGGGcGTGGT) (GGGCGG)]
75277745–75277835 TEF-2 (2) [GGGTGTGG] AML1 (1) [TGTGGT]
SpRunT-1(1) [TGTGGTC] Core-binding factor (1)[TGTGGTCA]
C/EBPAlpha (1) [CGTTGCNNNGCAAcG]
AP-2 (1) [GCCCAGCA] CP1 (1) [GATTGG]
CACCC-binding factor (1) [GGGTGG] AP-1 (1) [TGCGTCA]
XPF-1 (1) [CAGCTG] E4F1 (1) [CGTNACG]
AK170206
AK036748
(mmu-mir-223)
X(+) DEF (1) [TTGTCAgTTT] H4TF-1 (1) [GATTTC]
92442511–92442611 HNF-1 (1) [GGTTAG] BBF1 (1) [ACTTTA]
GATA-1 (1) [TTATCT] PU.1 (2) [TTCCTC]
NF-ATp (1) [TGTTTCCT (TTTCCTC)] C/EBPa (1) [TCATGACACCAt]
AK044422
(mmu-mir-124a-1)
14(+) Sp1 (3) [GGGCAG (GGGGGAGGGG) (GGGGC{C/G}GGGC)]
63542041–63542225 bZIP911 (1) [gGTGACGTGTGC] E4F1 (1) [GTGACGT]
ATF (1) [TGACGT] bZIP910 (1) [TGACGTG]
bZIP911 (1) [TGACGTGT] HiNF-C (1) [GAGGGcGGGG]
BGP1 (1) [GGGGGGG(7-16)] Pur-1 (1) [AGGGGGGGGGTG]
NF-S (1) [YGTCAGC] E47 (1) [CAGATG]
PU.1 (1) [CTTCTC] C-MyC (1) [TCTCTTA]
Tll (1) [AATAATCC] Kr (1) [tTAATCCGTT]
C-ETs-2 (1) [AAGGAA] N-OCT-3 (1) [MATNNWAAT]
MEF-2 (1) [TTATTTTTAA(YTWWAAAtAR)]
AnTp (1) [TAATTaTTAAA] SEF4 (1) [RTTTTTR]
Dof2 (1) [AAAAAGGAgC]
AK018276
(mmu-mir-433)
12(+) PU.1 (4) [TTCCTC] GR (6) [TCTTCT]
110039132–110039250
AK049271
(mmu-mir-546)
10(+) HiNF-C (1) [GAGgGCGGGG] CAC-binding protein (1) [GGGGTG]
126381790–126381867 CACCC-binding factor (1) [GGGTGG] PuF (1) [GGGTGGG]
Sp1 (2) [GGTGGG (gGGGGAGGGGa)]
TTF-1 (1) [GCNCTNNAG] Adf-1 (1) [GCYGYyGYCGY]
HFH-8 (1) [TGTTTATNYR] ANF (1) [cTTTATCTGG]
GATA-1, -2, -3 (1) [TTATCT] MAZ (1) [GGGAGGG]
NF-Atp (1) [GGAGCC] IL-6 RE-BP (1) [CTGGAA]
C/EBPb (1) [CTGGRAA]
AK133839
(mmu-mir-686)
14() Sp1 (1) [GAGGgGTGGT] AML1 (1) [TGTGGT]
53572279–53572320622 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.
Table 2. Continued
cDNAs (miRNAs)
Chromosome, Strand,
Positiona Transcription Factors and Consensus Sequences
AK163187
(mmu-mir-698)
4(+) IL-6 RE-BP (1) [CTGGGA] Zmhox1a (1) [GCTGcCCGTC]
124244095–124244140
AK030571
(mmu-mir-707)
7(+) N-Oct-3 (1) [MATNNWAAT] GCF (2) [NNGCGGGGCN]
44717300–44717355
Predicted transcription factors that bind to highly conserved, upstream regions of cDNA sequences.
a The position of conserved genomic regions.
bDenotes number of binding sites.activity. Two kinds of DN-PU.1 constructs with deletions
of distinct regions in the transactivation domain were pre-
pared (Figure S3C). We then examined actions of DN-
PU.1 onmousepri-miR-223promoter activity using a lucif-
erase reporter assay and observed that the expression ofPU.1DAD, but not PU.1DGD, significantly repressed the pro-
moter activity, demonstrating that PU.1 plays a significant
role in mouse pri-miR-223 transcription and that the acidic
domain of PU.1 is critical for transcriptional control of
mouse pri-miR-223 (Figure 3B).Figure 2. PU.1 and C/EBPb Activate Mouse Pri-miR-223 Promoter
(A) Interactions of PU.1 and C/EBPb with the core promoter region of mouse pri-miR-223 were examined in WEHI-3 cells using ChIP assay as de-
scribed in Experimental Procedures. As controls, Cathepsin C promoter (positive control) and c-Myc promoter (negative control) were assayed.
Two percent of input DNA was used as a positive control of PCR. The antibody against MKP-1 was used as negative control for ChIP.
(B) A graded amount (1[0.5 mg], 1/3, and 1/9) of each expression vector together with reporter vectors (Firefly Luc (FL): 0.2 mg; Renilla Luc (RL): 0.05 mg)
was transfected into NIH3T3 cells and assayed for a luciferase reporter assay.
(C) A graded dose (1[0.3mg], 1/3, and 1/9) of C/EBPb expression vector together with PU.1 expression plasmid (0.2 mg) and reporter vectors (FL:
0.2 mg; RL: 0.05 mg) were transfected in NIH3T3 and examined for the pri-miR-223 promoter activity by a luciferase reporter assay.
(D) A graded amount (1[0.5mg], 1/3, and 1/9) of mouse GATA-1 expression vector together with reporter vectors (FL: 0.2 mg; RL: 0.05 mg) was trans-
fected into RAW264.7 cells and examined for pri-miR-223 promoter activity by a luciferase reporter assay. All data are represented as mean ± stan-
dard deviation (SD) from triplicate assays.Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 623
Figure 3. PU.1 as Well as C/EBP as a Regulator of Pri-miR-223 Transcription
(A) The mutant sequences of mouse pri-miR-223 promoter reporter vector are shown (left). The effects of mutations on endogenous pri-miR-223
promoter activity were examined by a luciferase reporter assay. Data are shown as promoter activity relative to the basal endogenous pri-miR-
223 promoter activity.
(B andC) Repression of the endogenousmouse pri-miR-223 promoter activity by overexpression of dominant-negative PU.1 (DN-PU.1; B) or C/EBPb
(C). Together with reporter vectors (FL: 0.2 mg, RL; 0.05 mg), indicated expression vectors (0.5 mg) were transfected into RAW264.7 cells. The activity of
mouse pri-miR-223 promoter was then examined by a luciferase reporter assay. For DN-PU.1 expression, each expression vector was used with two
doses (1[0.5mg] or 1/10). Data are represented as mean ± SD from triplicate assays. * indicates p < 0.05 in a Student’s t test.
(D) The levels of pri-miR-223 and mature miR-223 in RAW264.7 cells transfected with either pcDNA3, DN-PU.1 (PU.1DAD), or DN-C/EBPb were ex-
amined by quantitative real-time RT-PCR as detailed in the Experimental Procedures. Transfectants were enriched as described in the Supplemental
Data. Data are shown as mean ± SD from triplicate measurements.
(E) The level of pri-miR-223 in undifferentiated and differentiatedM1 cells was examined by quantitative real-time RT-PCR. Data are shown asmean of
triplicate assays.
(F) Stable transfectants of M1 cells with either control (pcDNA3) or DN-PU.1 (PU.1DAD) expression vector were prepared as described in the Supple-
mental Data and were cultured in the presence of mrIL-6 for 4 days to induce differentiation. The level of pri-miR-223 in each transfectant was then
examined by quantitative RT-PCR. Data are represented as mean ± SD from triplicate tests.624 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.
In addition to the assays with DN-PU.1, effects of dom-
inant-negative C/EBPb (DN-C/EBPb) expression on the
pri-miR-223 promoter activity were also examined, and
reduction of the promoter activity was observed as well,
confirming a significant role of C/EBPs in activation of
the pri-miR-223 promoter (Figure 3C).
Consistent with the roles of PU.1 and C/EBPb in pri-
miR-223 promoter activation, endogenous levels of pri-
and mature miR-223 were significantly downregulated
by the expression of DN-PU.1 (PU.1DAD) or DN-C/EBPb
in RAW264.7 cells (Figure 3D).
Regulation of pri-miR-223 by PU.1 further implicates
that the inducible level of miR-223 expression would be
synchronous with myeloid differentiation. Indeed, we
observed significant upregulation of pri-miR-223 level
in M1 cells along with IL-6-induced differentiation into
macrophage-like cells (Figure 3E). Consistent with the
above results, PU.1 appeared as a critical regulator also
for differentiation-induced pri-miR-223 upregulation in
M1 cells. The M1-PU.1DAD line that is stably transfected
with PU.1DAD vector demonstrated a significantly lower
level of pri-miR-223 than that in the M1-mock line after
IL-6-induced differentiation (Figure 3F); this also indicates
a significant role of PU.1 in pri-miR-223 regulation during
myeloid differentiation.
Taken together, our observations indicated that hema-
topoietic transcription factor PU.1 as well as C/EBPb are
key transcription factors for pri-miR-223 transcription
and, therefore, for miR-223 expression.
Regulation of Human miR-223
Given the mechanism for miR-223 expression in the
mouse system, we realized a difference between our re-
sults and the previous work reporting the mechanism of
human miR-223 regulation (Fazi et al., 2005). Hence, we
sought to re-examine human miR-223 regulation.
We first searched for the candidate transcript of
human pri-miR-223 and found one registered transcript,
LOC389865 RNA (XM_374329), which encodes human
pre-miR-223 sequence (Figure 4A). This transcript is actu-
ally expressed in human bone marrow as detected by RT-
PCR (Figure 4A). We then cloned the transcript, and two
alternative splicing forms were obtained (Figure 4B). A ge-
nome plot of these transcripts demonstrated that this
gene has a conventional exon-intron structure as ob-
served in the mouse miR-223 gene (Figure 4B).
As LOC389865 may not be full-length transcript, we
next performed rapid amplification of cDNA ends (RACE)
to obtain the information from its 50 end. This assay would
also be informative in discovering whether other alterna-
tive transcripts are present or not. We obtained two dis-
tinct 50 RACE products and estimated the consistent
lengths for the scales from two alternative splicing forms
of human pri-miR-223 (Figure 4C). We then sequenced
a total of 36 clones of the RACE products, and 34 clones
indicated the exact same transcription start site; also, the
other two clones pointed to two sites that are near the
major transcription start site (Figure 4D, lower panel).The region proximal to the transcription start sites of
human pri-miR-223 is that genomic region that is highly
conserved among different species and is actually homol-
ogous to the core promoter of mouse pri-miR-223
(Figure 4D). A reporter assay similar to one in Figure 1C
revealed that the 50-flanking genomic region of cloned
human pri-miR-223 has a potent promoter activity in hu-
man monocytic leukemia cell lines, THP-1 and U-937,
both of which express a substantial level of miR-223 (Fig-
ure 4E). Moreover, the deletion of the conserved region
completely abolished the promoter activity, showing the
promoter structure similar to that of mouse pri-miR-223
(Figure 4E).
Together, our results strongly indicate that, under phys-
iological condition, human miR-223 is probably regulated
by the conserved promoter identified in our study as ob-
served in the mouse miR-223 gene.
Regulation of miR-223 in Acute Promyelocytic
Leukemia Cells
We then sought to reassess the regulation of miR-223 in
the exactly same experimental system adopted in the pre-
vious work (Fazi et al., 2005).
We first determined the transcription start sites of pri-
miR-223 in both nontreated and ATRA-treated NB4 cells.
Two relatively abundant RACE products (RP1 and RP2)
and one minor product (RP3) were obtained in ATRA-
treated NB4 cells (Figure 5A). In addition to these prod-
ucts, another minor RACE product (RP4) was detected
in nontreated NB4 cells (Figure 5A). Cloning and sequenc-
ing of the RACE products revealed that transcripts repre-
sented by RP1, RP2, and RP4 are all generated from the
exact same major transcription start site identified in the
bone marrow sample (Figure 5A, lower panel). The RP4
is the other splicing variant of human pri-miR-223, which
was undetectable in either bone marrow or ATRA-treated
NB4 cells. The minor product, RP3, was undetectable in
bone marrow RNA, and this revealed one alternative tran-
scription start site at 2039 bp downstream of the major
transcription start site (Figure 5A, lower panel). Despite
the presence of this minor transcription start site, we
were convinced that pri-miR-223 in NB4 cells is mainly
transcribed from the exact same major transcription start
site identified in human bone marrow. Although it is re-
ported that some pri-miRNAs are hardly detectable due
to Drosha activity (Lee et al., 2004), this is not the case
for pri-miR-223 since the repertoire of pri-miR-223 tran-
scripts in NB4 cells is not altered even by siRNA-mediated
Drosha knockdown (Figure S4A).
Using a specific primer set detecting only the major
pri-miR-223 transcripts (Figure 5B, middle), we found that
the major variants were upregulated in NB4 cells upon
ATRA treatment and that this increase of pri-miR-223
was correlated with the upregulation of mature miR-223
(Figure 5B, lower panel). Strikingly, the promoter contain-
ing the conserved genomic region was highly activated
in NB4 cells during ATRA-induced differentiation (Fig-
ure 5C), consistent with the upregulation of pri-miR-223Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 625
Figure 4. Cloning and Characterization of Human Pri-miR-223 in Bone Marrow
(A) Detection of the putative human pri-miR-223, LOC389865 mRNA, in bone marrow cDNA by RT-PCR with indicated primers.
(B) Cloning of human pri-miR-223. Two alternative splicing forms (Long, L, and Short, S) were cloned as human pri-miR-223, and their genome plots
are shown. Numbers denote the position at H. sapiens genomic clone, RP6-159A1 from Xq12-13.3.
(C) Cloning of full-length 50 ends of human pri-miR-223. Full-length transcripts were purified from bone marrow total RNA or HeLa cells and were
reverse transcribed with GSP3 to obtain full-length human pri-miR-223 50 ends.
(D) Schematic for positions of the conserved genomic region, identified transcription start sites, and pre-miR-223 sequence (upper panel). Details of
sequences around the transcription start sites of human pri-miR-223 are shown (lower panel). Shaded region indicates the conserved site as shown in
Figure 1D and contains the core promoter region. Faint letters denote the first intronic sequence of human pri-miR-223. MTSS indicates major
transcription start site. Thin arrows indicate the positions of minor transcription start sites.
(E) Luciferase reporter assays were performed in either THP-1 or U937 cells using indicated reporters. 1 indicates ppri-hmiR-223669-Luc, 2 indicates
ppri-hmiR-223293-Luc, 3 indicates ppri-hmiR-223198-Luc, 4 indicates ppri-hmiR-22396-Luc, 5 indicates ppri-hmiR-22316-Luc, and 6 indicates
pGL3 basic.and the resultant mature miR-223 level in NB4 cells by
ATRA treatment.
The roles of PU.1 and C/EBPa in the ATRA-induced
pri-miR-223 promoter activity were also examined using
RNAi against these molecules. Knockdown of PU.1 re-
sulted in a significant reduction of basal and ATRA-
induced pri-miR-223 promoter activity (Figure 5D). The
ATRA-inducible pri-miR-223 promoter activity was slightly
reduced by a siRNA against C/EBPa (Figure 5D). Consis-
tently, the endogenous level of pri-miR-223 in ATRA-
treated NB4 cells was significantly repressed by knock-
down of PU.1 using shRNA expression-vector-based
RNAi (Figures 5E and 5F). Again, RNAi against C/EBPa
resulted in only a slight reduction of ATRA-induced pri-626 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.miR-223 upregulation (Figures 5E and 5F). The levels of
mature miR-223 were also assayed at the same time
and found to be consistent with the levels of pri-miR-223
(Figure S4B). Weak effects of C/EBPa knockdown in the
above assays are probably due to redundant activities of
other inducible C/EBP members such as C/EBPb (K.K.
and T.F., unpublished data; Duprez et al. 2003) during
ATRA-induced differentiation of NB4 cells. Indeed, we ob-
served more effective reduction of the promoter activity
and endogenous level of pri-miR-223 in ATRA-treated
NB4 cells transfected with DN-C/EBPb that would sup-
press actions of multiple C/EBPs (Figures S4C and S4D).
With these results taken together, we concluded that the
conserved genomic region acts as pri-miR-223 promoter
in steady state and during ATRA-induced differentiation of
NB4 cells and is probably driven by PU.1 and C/EBPs as
observed in the mouse miR-223 regulation.
DISCUSSION
Lineage specificity of miR-223 expression is strict as it is
detected exclusively in the myeloid compartment of the
hematopoietic system (Chen et al., 2004; Figure S2). In
this study, we concluded that myeloid expression of
miR-223 might be specified by the conserved 50 proximal
cis-regulatory element that the myeloid transcription fac-
tors, PU.1 and C/EBP, cooperatively act on. In myeloid
lineage, there is no single master transcription factor
that alone governs myeloid differentiation as seen with
Pax5 in B lymphopoiesis (Sieweke and Graf, 1998; Fried-
man, 2002; Zhu and Emerson, 2002; Rosmarin et al.,
2005). Instead, multiple transcription factors work cooper-
atively and coordinately to control myeloid gene expres-
sion (Sieweke and Graf, 1998; Friedman, 2002; Rosmarin
et al., 2005; Tenen et al., 1997). Although more than
a dozen transcription factors are known to play critical
roles in myeloid gene expression (Sieweke and Graf,
1998; Friedman, 2002; Rosmarin et al., 2005), PU.1 and
C/EBPs are particularly important as they regulate numer-
ous myeloid genes and are specifically required for mye-
loid differentiation (Sieweke and Graf, 1998; Friedman,
2002; Rosmarin et al., 2005; Tenen et al., 1997). In this
view, together with its myeloid-specific expression, miR-
223 would now be categorized as a member of the
so-called ‘‘myeloid genes.’’ Neither PU.1 nor C/EBP is
truly myeloid restricted since PU.1 is also found in B cells,
and C/EBPs are expressed in multiple organs such as liver
and adipocytes (Rosmarin et al., 2005). Therefore, mye-
loid-specific expression of miR-223 probably requires
both of these transcription factors. In the presence of
a substantial amount of PU.1, C/EBPb could activate the
core promoter in a dose-dependent manner (Figure 2C),
indicating that both PU.1 and C/EBP are required for the
proper activation of the pri-miR-223 promoter. Together,
we speculate that high-level PU.1 confers stable inducibil-
ity of the pri-miR-223 promoter activity, and the C/EBP
level determines magnitude of the promoter activation in
myeloid cells. This idea is consistent with the notion that
miR-223 is upregulated during the myeloid differentiation
that is associated with increase of PU.1 and C/EBP levels.
In addition, we observed repression of endogenous activ-
ity of pri-miR-223 promoter by overexpression of erythroid
transcription factor, GATA-1 (Figure 2D). This indicates
a critical regulatory role of the conserved element in deter-
mining pri-miR-223 expression at the turning point of
lineage choice between myeloid and erythroid fates,
showing an analogy to the regulation of other myeloid
genes (Sieweke and Graf, 1998).
Through careful molecular analyses, our study contra-
dicts some aspects of a previous study (Fazi et al.,
2005). The miR-223 is evolutionarily conserved, and its
expression pattern during myeloid differentiation is alsosimilar in human and mouse systems. However, we did
not find the unique C/EBPa-binding element that overlaps
with NFI-A-binding site in mousemiR-223 gene, suggest-
ing that the previously proposed machinery reported in
human miR-223 regulation might not be a conserved
mechanism of miR-223 regulation. In general, critical ge-
nomic elements regulating gene transcription have been
conserved during evolution. Furthermore, it has been pro-
posed that the essential genomic elements of miRNAs, in-
cluding the precursor sequences, might be evolutionary
conserved (Berezikov et al., 2005).
Fazi et al. (2005) performed most of their experiments
based on the assumption that the unique element for C/
EBPa and NFI-A lies in the promoter that they identified
for the human miR-223. However, the transcription start
sites of human pri-miR-223 that we identified in this study
indicated a distinct promoter site. Major transcription start
sites are found in a genomic region at a rather large
distance from the pre-miR-223 sequence. This region is
adjacent to the core promoter of pri-miR-223, which was
initially found to be the genomic region highly conserved
among different species, including human, mouse, rat,
and dog. According to our study, the unique element for
C/EBPa and NFI-A competition actually lies in the second
intronic region. Therefore, it was still thought to be possi-
ble that the element would act as an intronic regulatory
element such as an intronic enhancer or repressor. In
many cases, intronic regulatory elements are also evolu-
tionarily conserved (Himes et al., 2001). However, there
are a few exceptional cases reporting nonconserved in-
tronic enhancers such as in the human adiponectin gene
(Qiao et al., 2005). However, even this possibility is unlikely
since we could not observe any effects of the intronic se-
quence on the activity of actual promoter we defined
(Figure S4E). Therefore, the actual role of the intronic
domain should be revisited in future investigations.
We believe that our study clearly demonstrated the im-
portance of gaining information on pri-miRNAs and neigh-
boring genomic elements for studying miRNA expression.
In this view, our approach of finding cDNAs encoding
miRNA precursors and following genomic profiling was
successful and demonstrated that previously established
databases are rich sources of primary miRNA transcripts.
Because the databases, like FANTOM3, can provide some
information on the tissue origin of each cDNA collection
(Yamanaka et al., 2001; Okazaki et al., 2002) in association
with EST databases, for example, we can estimate tissue-
expression patterns of desired miRNAs by tracing distri-
bution atlases of pairing cDNAs. Indeed, in this study,
we could confirm this idea and found an overlapping tis-
sue-expression pattern of miR-223 and its primary tran-
script, AK036748 (Table 1; Figure S2). In the FANTOM3
database, cDNAs were cloned using the Cap-trapper
method that accumulates mRNAs with Cap structure,
generating a trustworthy full-length cDNA library (Carninci
et al., 2000; Carninci and Hayashizaki, 1999). Determining
the exact transcription start sites is a necessary process
for analyzing transcriptional regulation of pri-miRNAs,Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 627
Figure 5. miR-223 Regulation during ATRA-Induced Differentiation of NB4 Cells
(A) Transcription start sites of pri-miR-223 in NB4 cells were determined by 50 RACE. The 50 RACE products (RPs) from total RNA samples of bone
marrow (BM), NB4 cells (None), ATRA-treated NB4 cells, and HeLa cells are shown (upper panel). M1 indicates 100 bp step ladder; M2 indicates 1 kb
DNA ladder (G5711, Promega). The transcription start sites indicated by the 50 RACE products are shown (lower panel).
(B) Detection of the human pri-miR-223, LOC389865 mRNA, in ATRA-treated and non-treated NB4 cells using PCR with primer set 3 as indicated in
Figure 4A (upper panel). BM indicates bone marrow; 35 indicates five times more RNA template; and DW indicates distilled water. M1 indicates
100 bp step ladder; M2 indicates 1 kb DNA ladder (G5711, Promega). (Middle panel) The target site of human pri-miR-223 for a specific primer
set for real-time PCR is shown. (Lower panel) Upregulation of pri-miR-223 (left) and mature miR-223 (right) during ATRA-induced differentiation of
NB4 was observed by quantitative real-time PCR.
(C) Potent activation of the conserved pri-hmiR-223 promoter in NB4 cells during ATRA-induced differentiation. Luciferase reporter assay was
performed as described in Experimental Procedures. 1 indicates ppri-hmiR-223669-Luc, 2 indicates ppri-hmiR-223293-Luc, 3 indicates ppri-
hmiR-223198-Luc, 4 indicates ppri-hmiR-22396-Luc, 5 indicates ppri-hmiR-22316-Luc, and 6 indicates pGL3 basic. Data are shown as mean ±
SD of triplicate measurements.628 Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc.
and, therefore, our strategy of adopting FANTOM3 was
feasible and allowed us to perform a genomic analysis
by searching the highly conserved genomic region proxi-
mal to the transcription start sites. Such conserved re-
gionswere supposed to be critical cis-regulatory elements
that are actually gene promoters. Here, we could demon-
strate that this genome-based analysis lead to the identi-
fication of a highly conserved genomic region proximal
to the pri-miR-223 transcription start sites that is the actual
core promoter and most likely determines myeloid-
specific expression of this miRNA. Further, we could iden-
tify PU.1 and C/EBP transcription factor-binding motifs,
suggesting our approach might prove useful for studying
the regulation of othermiRNAs. Because gene-expression
pattern is regulated by the unique combination of tissue-
specific transcription factors, knowing that a specific set
of transcription factors binds to a conserved genomic
element would give clues for the tissue- and/or cellular-
expression pattern of a specific miRNA. Our strategy
would also be prominent in this view since many miRNAs
have not yet been precisely characterized for their expres-
sion patterns and regulatory mechanisms.
Upon the homology search for cDNAs encoding pre-
miRNAs, we identified a total of 42 complete pairings of
cDNA-pre-miRNAs and practically complete pairings for
33miRNAs. Further screening for miRNAswith highly con-
served genomic regions around the transcription start
sites resulted in the identification of ten miRNAs that fit
the criterion. Since hundreds ofmiRNAs have been cloned
to date (Bartel and Chen, 2004; Bentwich et al., 2005), this
number appears to be very small. However, we should
note that cDNAs as putative pri-miRNA candidates pre-
sented in this study are for so-called ‘‘exonic’’ miRNAs
(Kim and Nam, 2006). There are many miRNAs derived
from intronic regions of mRNA-like RNAs that are desig-
nated as ‘‘intronic’’ miRNAs (Kim and Nam, 2006). Indeed,
a preliminary screening for pri-miRNAs of intronic miRNAs
that used a similar approach identified candidate cDNA
clones for more than 100 miRNAs (Y.F. and T.F. unpub-
lished data), with many of them bearing conserved geno-
mic elements.
In summary, by exploiting the combination of bioinfor-
matics and biological approaches, we found a transcrip-
tional mechanism for the myeloid expression of mouse
miR-223 that is conserved in human miR-223 regulation.
Our study thus proposes an evolutionarily conserved
mechanism for miR-223 expression, and we propose an
alternative to the previous model of Fazi et al. (2005).
Further investigation will have to clarify which of the two
mechanisms contributes to the regulation of miR-223,
whereby the two need not be mutually exclusive.EXPERIMENTAL PROCEDURES
Bioinformatics
Extraction of mRNA-like RNAs Encoding miRNA Precursor
Sequences
A total of 337 precursor sequences ofMus musculusmiRNA were ob-
tained from the miRBase Sequence Database, Release 8.1 (http://
microrna.sanger.ac.uk/sequences/ftp.shtml; Griffiths-Jones, 2004).
The Riken FANTOM3 database provides mouse nonredundant, full-
length cDNA sequences, and a total 102,802 of those sequences
were downloaded (ftp://fantom.gsc.riken.jp/FANTOM3/). A homology
search was exhaustively conducted between miRNA precursor se-
quences and cDNA sequences by using BLAST 2.2.12 with a cutoff
value of E = 1.0e5. Among resultant cDNA-pre-miRNA pairs (294 pairs
for 61 miRNAs), those with a perfect homology were extracted.
Analyses of Transcription Factor-Binding Sites
and Genome Conservation
To identify the transcription start site, cDNA sequences containing
pre-miRNA were mapped to the mouse genome, referring to the
NCBI database (http://www.ncbi.nlm.nih.gov). Phylogenetic conser-
vation from 250 bp upstream sequence of each 50 boundary was ana-
lyzed in a Mouse BLAT search of the UCSC Genome Browser (http://
genome.ucsc.edu/cgi-bin/hgGateway). Putative binding sites for
transcription factors of conserved genomic regions were explored by
conducting the Transcription Element Search System (http://www.
cbil.upenn.edu/tess/index.html).
Cell Culture, Transfection, and DNA Constructs
Conditions of cell cultures and transfections are detailed in the Supple-
mental Data. Details of plasmid constructions are also described in the
Supplemental Data.
Chromatin Immunoprecipitation Assay
ChIP was performed with Chromatin Immunoprecipitation Assay Kit
(UpstateBiotechnology, Charlottesville, VA) according to themanufac-
turer’s recommendation. Antibodies used for ChIP were all purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Genomic regions
corresponding to promoters of mouse pri-miR-223, Cathepsin C, and
c-Mycwere amplifiedbyPCRusing specific primers shown inTableS1.
Quantitative Real-Time RT-PCR
Total RNA was isolated from cells using mirVana miRNA Isolation Kit
(Ambion) or miRNeasy mini kit (Qiagen) with the protocol specialized
for total RNA purification. Relative quantification of human pri-miR-
223 was performed by real-time PCR with SYBR green I. Level of
mouse pri-miR-223 was determined with Taqman technology. Primers
amplifying themousepre-miR-223 region anda specific Taqmanprobe
were designed with PrimerExpress software (Applied Biosystems).
TaqmanMicroRNA Assay (Applied Biosystems) technology with a ma-
ture miR-223-specific probe and RT and PCR primers were used for
quantification of mature miR-223, according to the manufacturer’s in-
structions. Amplification of HPRTmRNA (for pri-miR-223; Applied Bio-
systems) and U6 small RNA (for mature miR-223; Applied Biosystems)
was done with each experimental sample as an endogenous control to
account for differences in the amount and quality of total RNA added to
each reaction. All primers and theTaqmanprobeare shown inTableS1.(D) Effects of synthetic siRNA-mediated PU.1 or C/EBPa knockdown on ATRA-induced pri-miR-223 promoter activity. NC indicates negative control.
Data are shown with mean ± SD of triplicate measurements.
(E and F) Knockdown of PU.1 (left) or C/EBPa (p42 isoform; right) by corresponding shRNA vectors was confirmed by western blotting (E). Note that
there is significant upregulation of PU.1 upon ATRA-treatment as reported previously (Mueller et al., 2006). A portion of each sample was subjected to
measurement of the pri-miR-223 level (F). Transfectants were enriched as described in the Supplemental Data. Data in (F) were shownwithmean ±SD
of triplicate assays.Cell 129, 617–631, May 4, 2007 ª2007 Elsevier Inc. 629
RACE
Total RNA from human bone marrow was obtained from Clontech and
used for 50 RACE. For isolation of total RNA fromNB4 cells and to avoid
any loss of small RNA fractions, we used the mirVana miRNA Isolation
Kit or the miRNeasy mini kit (Qiagen) with the protocol specialized
for total RNA purification. The 50 RACE was performed using the
GeneRacer kit (Invitrogen). RACE products were obtained by PCR
using TaKaRa Ex Taq (TAKARA Bio. Inc., Tokyo, Japan) with the sense
primer provided in the GeneRacer kit and the antisense primer specific
for human miR-223 gene listed in Table S1 and were sequenced to
determine 50 ends of human pri-miR-223. For sequencing, RACE
products were separated on agarose gels by electrophoresis, and in-
dividual bands were cloned using pGEM-T Easy Vector Systems
(Promega).
RNA Interference
Knockdown of hPU.1 and hC/EBPa by RNAi was accomplished by
transfections of either duplex siRNAs (for the promoter-reporter assay)
or shRNA expression vectors. Duplex siRNAs were synthesized by
Japan Bio Services Co., LTD. (Saitama, Japan). Both synthetic and
vector-based siRNAs target the same sites in corresponding transcrip-
tion-factor mRNAs, and the sequences are shown in Table S1. The
RNAi target sites for hPU.1 and hC/EBPa have been evaluated empir-
ically and literally (Mueller et al., 2006). AllStars Negative Control siRNA
was purchased from Qiagen and was used as the negative-control
synthetic siRNA.
Western Blotting
Western blotting was performed as described previously (Fukao et al.
2002) and is also detailed in the Supplemental Data. Affinity-purified
rabbit anti-PU.1 and -C/EBPa antisera were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-b-actin antibody was
purchased from Sigma.
Supplemental Data
Supplemental Data include Experimental Procedures, References,
four figures, and one table and can be found with this article online
at http://www.cell.com/cgi/content/full/129/3/617/DC1/.
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